06.2021
APIM Therapeutics has presented a poster summarizing results from its on-going first-in-human clinical study with ATX-101 in advanced cancer patients during the Developmental Therapeutics-Molecular Targeted Agents and Tumor Biology Poster Session at the American Society of Clinical Oncology (ASCO) Annual Meeting. A copy of the presented poster can be downloaded here.
06.2021
05.2021
APIM Therapeutics announced today completion of a private placement round by existing and new investors. With the proceeds from the private placement, the company will initiate a proof-of-concept combination study in recurrent ovarian cancer and support a Phase-2 investigator-initiated study in sarcoma. For a copy of the corresponding press release, please follow this link.
05.2021
APIM Therapeutics announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug application (IND) for a Phase 1b/2a clinical trial to investigate ATX-101 in combination with platinum-based therapy in ovarian cancer. The trial will be conducted in Australia, South Korea and Taiwan. A copy of the corresponding press release is provided here.
01.2020
Ventac Partners announces the launch of Ambulero, a Miami-based spin-out of the University of Miami Miller Medical School focused on new gene and cell therapy approaches for treating vascular disease. For more information please visit www.ambulero.com.